Corbus Pharmaceuticals (NASDAQ:CRBP) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.05), MarketWatch Earnings reports. The company had revenue of $1.09 million for the quarter, compared to analyst estimates of $1.66 million.

NASDAQ:CRBP traded down $0.26 on Friday, hitting $6.61. The company had a trading volume of 942,460 shares, compared to its average volume of 1,131,068. The company has a market cap of $435.91 million, a price-to-earnings ratio of -10.17 and a beta of 2.16. Corbus Pharmaceuticals has a 52 week low of $4.50 and a 52 week high of $9.95.

Several brokerages recently commented on CRBP. ValuEngine raised shares of Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 1st. BidaskClub downgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 18th. Cantor Fitzgerald reissued a “buy” rating and issued a $36.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, October 22nd. Finally, B. Riley began coverage on shares of Corbus Pharmaceuticals in a research note on Wednesday, October 24th. They issued a “buy” rating and a $22.00 price objective for the company. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $27.33.

Hedge funds have recently added to or reduced their stakes in the company. Nexthera Capital LP bought a new position in shares of Corbus Pharmaceuticals during the second quarter valued at $678,000. Woodstock Corp raised its stake in shares of Corbus Pharmaceuticals by 29.5% during the third quarter. Woodstock Corp now owns 93,264 shares of the biopharmaceutical company’s stock valued at $704,000 after acquiring an additional 21,263 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Corbus Pharmaceuticals by 2,742.5% during the first quarter. Royal Bank of Canada now owns 51,961 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 50,133 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Corbus Pharmaceuticals by 12.0% during the second quarter. IFP Advisors Inc now owns 1,500,805 shares of the biopharmaceutical company’s stock valued at $7,579,000 after acquiring an additional 160,250 shares during the last quarter. Finally, Alps Advisors Inc. bought a new position in shares of Corbus Pharmaceuticals during the second quarter valued at $419,000. 42.69% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Corbus Pharmaceuticals (CRBP) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/11/10/corbus-pharmaceuticals-crbp-issues-quarterly-earnings-results-misses-estimates-by-0-05-eps.html.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

Further Reading: Does the discount rate affect the economy?

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.